Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Labor Lawyers, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, File Lawsuit, Against Nurse Logistics, Inc., for Allegedly Failing to Provide Employees With Accurate Wages


Law Office of Blumenthal Nordrehaug Bhowmik De Blouw LLP

For more information about the class action lawsuit against Nurse Logistics, Inc., call (800) 568-8020 to speak to an experienced California employment attorney today.

The San Francisco employment law attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, filed a class action lawsuit against Nurse Logistics, Inc., alleging the company violated the California Labor Code. The lawsuit against Nurse Logistics, Inc. is currently pending in the Santa Clara County Superior Court, Case No. 22CV408939. To read a copy of the Complaint, please click here.

According to the lawsuit filed, Defendant allegedly (a) failed to pay minimum wages, (b) failed to pay overtime wages, (c) failed to provide legally required meal and rest periods, (d) failed to provide accurate itemized wage statements, (e) failed to reimburse employees for required expenses, and (f) failed to provide wages when due, all in violation of the applicable Labor Code sections listed in California Labor Code Sections §§ 201, 202, 203, 226, 226.7, 510, 512, 1194, 1197, 1197.1, 2802, and the applicable Wage Order(s), and thereby gives rise to civil penalties as a result of such alleged conduct.

Nurse Logistics, Inc. allegedly failed to reimburse employees for required business expenses. California Labor Code § 2802 expressly states that “an employer shall indemnify his or her employee for all necessary expenditures or losses incurred by the employee in direct consequence of the discharge of his or her duties…” During employment, Plaintiff and other California Class Members were allegedly required to use their personal cellular phones and personal home offices as a result of and in furtherance of their job duties.

For more information about the class action lawsuit against Nurse Logistics, Inc., call (800) 568-8020 to speak to an experienced California employment attorney today.

Blumenthal Nordrehaug Bhowmik De Blouw LLP is a labor law firm with law offices located in San Diego County, Riverside County, Los Angeles County, Sacramento County, Santa Clara County, Orange County, and San Francisco County. The firm has a statewide practice of representing employees on a contingency basis for violations involving unpaid wages, overtime pay, discrimination, harassment, wrongful termination, and other types of illegal workplace conduct.

***THIS IS AN ATTORNEY ADVERTISEMENT***

Share article on social media or email:

Revolutionary Ten-Second Test for Early Detection of Periodontal Disease in Dogs, Cats


OraStripdx is a a revolutionary rapid test that can detect active periodontal disease in dogs and cats in ten seconds, with no anesthesia or sedation required.

“Periodontal disease is an invisible infection that causes needless suffering for millions of dogs and cats, so being able to test it this quickly and find it in its earliest stages is a major advantage to pet owners and their healthcare providers,” said John Beran, CEO of PDX BIOTECH.

PDX BIOTECH LLC today announced the official launch of OraStripdx, a revolutionary rapid test that can detect active periodontal disease in dogs and cats in ten seconds, with no anesthesia or sedation required. Each easy-to-use test strip changes color based on the concentration of thiols in the patient’s oral fluid. When a veterinarian or veterinary technician glides OraStripdx along the gumline of a dog or cat, thiols in the oral fluid will cause the test strip to change color, with the concentration of thiols reflecting periodontal disease activity.

“Periodontal disease is an invisible infection that causes needless suffering for millions of dogs and cats, so being able to test it this quickly and find it in its earliest stages is a major advantage to pet owners and their healthcare providers,” said John Beran, CEO of PDX BIOTECH, the parent company of OraStipdx. “In addition to periodontal disease itself causing pain, early detection can also serve as a warning sign of more serious disease.”

The performance of OraStripdx has been documented in peer-reviewed studies published in journals such as the Journal of the American Animal Hospital Association, the Journal of Veterinary Science & Technology and the Canadian Veterinary Journal. PDX BIOTECH has obtained five patents, and more than 250,000 tests have already been shipped to veterinary practices around the world.

The Science Behind OraStripdx

Approximately 85% of dogs and cats have periodontal disease. This chronic and progressive disease impacting multiple organ systems develops in the gingival sulcus, an anatomic compartment between the tooth and gum that cannot be visualized in the awake patient. PDX BIOTECH has developed technology to detect the development of disease where it cannot be directly visualized.

In dogs, cats, and even humans, the concentration of thiols in oral fluid is directly related to periodontal disease activity. Thiols, also called “volatile sulfur compounds” or VSCs, are structurally similar to alcohols but have a sulfur atom in place of an oxygen atom. In periodontal disease, the gingival sulcus becomes anaerobic as it deepens into a periodontal pocket. Each periodontal pocket harbors millions of pathogens. The most prominent of these pathogens are anaerobic bacteria that produce thiols as end-products of their metabolism. These pathogens degrade gingival tissue and alveolar bone, leading to loss of tooth attachment and, ultimately, cardiovascular, renal and hepatic sequelae.

The OraStripdx test strip is pre-treated with a thiol detection reagent. After the strip is glided along the maxillary gingival margin of a canine or feline patient, its color will reflect the concentration of thiols in the patient’s oral fluid. No color change means no detectable thiols and no active periodontal disease. Any color change reflects periodontal disease activity. The more intense the color, the higher the concentration of thiols, and the greater the periodontal disease. These visual results are easy for veterinary professionals to interpret and easy for clients to understand.

Advantages of Early Detection

Early detection of any disease can help prevent pain and suffering, as well as further progression of the condition. In peer-reviewed studies, OraStripdx was found to be significantly more effective than the visual awake exam in detecting active periodontal disease. This early detection enables timely intervention to prevent disease progression which may otherwise lead to tooth and bone loss as well as debilitating and life-threatening co-morbidities including cardiovascular, renal, and hepatic sequelae.

Early detection with OraStripdx also increases client compliance with veterinarian recommendations. In one peer-reviewed study, published in the Journal of Veterinary Science & Technology, routine use of the test in every wellness examination led to the following increases in client compliance with veterinarian recommendations:


  • 54% for professional cleaning under anesthesia
  • 57% for dental radiology
  • 80% for dental home care products.

Studies and scientific information about OraStripdx are available on the product’s website, orastripdx.com. Veterinary practices can purchase OraStripdx directly from the website.

# # #

About OraStripdx and PDX BIOTECH (orastripdx.com)

Manufactured in the U.S., OraStripdx is the premier product developed and produced by PDX BIOTECH, a growth-stage biotechnology company based in Louisville, Kentucky. The company is comprised of a core team of seasoned scientists and business leaders having over a century of combined experience, as well as an advisory board of global thought-leader veterinary clinicians. With the launch of OraStripdx, PDX BIOTECH intends to contribute every day to the long-term health and wellness of pets and their families worldwide.

Media Contact

Beth Strautz

(773) 895-5387

beth@vaguspr.com

Share article on social media or email:

Dr. Ella Faktorovich Continues Partnership With Exclusive Haute Beauty Network


News Image

She is committed to providing her patients with the most advanced vision correction treatments in LASIK and Cataract Surgery available worldwide.

Dr. Ella Faktorovich is among the leading ophthalmologists practicing in San Francisco. As an innovator in the development of advanced vision correction treatments, she has achieved worldwide acclaim for her contributions in the field of refractive surgery. Dr. Faktorovich founded Pacific Vision Institute more than twenty years ago. Under her leadership, Pacific Vision Institute is often the first in the Bay Area to bring the industry’s newest diagnostic and treatment technologies for LASIK and Cataract Surgery patients. Pacific Vision Institute has established a reputation for being chosen by eye doctors for their own LASIK.

Dr. Faktorovich has been featured on top tv news channels and in media articles for the latest in vision technology. She is listed in Best Doctors in America, Castle Connolly’s Top Doctor, and in the Top 100 Health Professionals in the World. She is committed to providing her patients with the most advanced vision correction treatments in LASIK and Cataract Surgery available worldwide.

Dr. Faktorovich is the founder and remains the Chair of the Annual San Francisco Cataract, Cornea, and Refractive Surgery Symposium dedicated to the continuing education of the Bay Area eye doctors in refractive surgery and other aspects of advanced patient eye care. She is the author of the first textbook on all-laser LASIK procedures, the first to outline the procedures in femtosecond laser applications in medicine and surgery. She is a recognized leader in this groundbreaking vision correction technique, with her definitive textbook used in educating eye surgeons around the world.

Learn more about Dr. Ella Faktorovich by visiting: https://hauteliving.com/hautebeauty/member/dr-ella-faktorovich/

ABOUT HAUTE BEAUTY NETWORK:

Haute Beauty is affiliated with the luxury lifestyle publication Haute Living. As a section of Haute Living magazine, Haute Beauty covers the latest advancements in beauty and wellness, providing readers with expert advice on aesthetic and reconstructive treatments through its network of acclaimed doctors and beauty experts.

For more about Haute Beauty, visit https://hauteliving.com/hautebeauty/

Share article on social media or email:

Dr. Ameer Ali Joins Physician Partners of America- Dallas, TX


Ameer Ali, M.D.

Physician Partners of America (PPOA) is pleased to announce that interventional pain management specialist Ameer Ali, M.D., has joined the company’s North Dallas, Texas pain management practice. He began seeing patients on January 3 at the office, located at 7515 Greenville Ave, Suite 500, Dallas, TX 75231.

Dr. Ameer Ali is a warm-hearted, board-certified, specialized Spine Care fellowship trained Interventional Pain Management Physician. Employing a multi-modal comprehensive treatment plan unique to each patient, Dr. Ali meticulously administers interspinous spacer implantation, radiofrequency ablation, neuromodulation, kyphoplasty for vertebral compression fractures, and intradiscal biologics for painful disc degeneration. His multi-modal methodology also includes a holistic and multidisciplinary approach enabling him to treat the whole person, taking into account mental and social factors.

After earning his Bachelor of Arts degree in Cell Biology & Neuroscience with magna cum laude from Rutgers University in New Jersey, Dr. Ali acquired his Interventional Spine and Musculoskeletal fellowship training at Virginia iSpine Physicians in Richmond, Virginia. He was privileged to be mentored by Dr. Michael DePalma, a nationally recognized spine care leader.

Dr. Ali enthusiastically focuses on providing superlative treatment which is of the essence for the appropriate management of these painful conditions. Since his aim is to help reduce pain and improve overall function, his most gratifying and ultimate outcome is correctly identifying and treating the pain generator. Therefore, instead of merely adjusting medications, the core of his treatment strategy optimizes desired results of significant improvement in overall pain, and thus quality of life.

He is a member of various professional associations inclusive of the American Academy of Physical Medicine and Rehabilitation, Spine Intervention Society, American Society of Interventional Pain Physicians, North American Spine Society, Texas Pain Society, and the Texas Medical Association.

Make an appointment with Dr. Ali by calling (469) 658-0151 or click here

About PPOA:

Physician Partners of America (PPOA) is a national healthcare organization focused on strengthening the doctor-patient relationship and improving patient outcomes. PPOA and its affiliates share a common vision to ensure the well-being of patients and provide its physician partners the opportunity to focus on the practice of medicine. This model allows physicians to be physicians, caring about patients and their needs versus the ever-complex administrative requirements. For more information about Physician Partners of America, visit http://www.physicianpartnersoa.com

Share article on social media or email:

The Weight Loss Surgery Center of Los Angeles, Known for Gastric Sleeve Surgery (Sleeve Gastrectomy) Expertise, Recognized as Top Patient Rated Bariatric Surgery Center


News Image

“We are proud to offer comprehensive medical and surgical weight loss solutions to help each patient embark on his or her path to health,” says Dr. David Davtyan.

The Weight Loss Surgery Center of Los Angeles has been selected as a 2023 Top Patient Rated LA Bariatric Surgery Clinic. This recognition from Find Local Doctors is a result of the numerous five-star ratings and positive reviews this clinic has received from patients through reputable online sources. Find Local Doctors is a user-friendly online directory, that helps consumers connect with skilled physicians in their area. The Weight Loss Surgery Center of Los Angeles is a private medical weight loss clinic, located in Beverly Hills. Dr. David Davtyan and his team have helped countless patients successfully deal with obesity and lose weight. They treat every patient as an individual and construct personalized treatment plans that fit unique needs and goals. The Weight Loss Surgery Center of Los Angeles offers a wide spectrum of cutting-edge medical endoscopic, surgical and minimally invasive weight loss procedures with excellent outcomes. They perform gastric balloons, gastric sleeve, endoscopic gastric sleeve (accordion procedure), Lap-Band and gastric plication. The experts at this clinic assist patients in overcoming weight loss challenges once and for all, so they can reclaim control of their bodies and wellness.

“We are proud to offer comprehensive medical and surgical weight loss solutions to help each patient embark on his or her path to health,” says Dr. David Davtyan.

More about Dr. David Davtyan:

Dr. David Davtyan is a well-recognized, highly respected weight loss surgeon with over 28 years of experience and has treated thousands of patients with exceptional results. He earned his medical degree from UCLA’s School of Medicine, where he was trained to treat extremely difficult and metastatic cancer cases. For over ten years, he devoted his career to helping patients fight successfully against cancer. In 2001 Dr. Davtyan himself had a successful bariatric surgery. The success he observed from the Lap-Band procedure prompted him to focus his practice entirely on performing weight loss procedures to transform his patients’ lives. He went on to study bariatric surgery in Belgium, where the Lap-Band was first introduced and became one of the first surgeons in the United States to offer the procedure once it achieved FDA approval in April of 2001. Dr. Davtyan and his team offer top-quality weight loss surgery (bariatric surgery) in Los Angeles, Orange County, and the Inland Empire, offering a spectrum of medical endoscopic, surgical and minimally invasive weight loss procedures with excellent outcomes. For more information please call 877-923-7546 or visit http://www.weightlosssurgeryla.com.

Share article on social media or email:

Memorial Healthcare System (Hollywood, FL) Relocates Sickle Cell Day Center, Names Medical Director


Foluso “Joy” Ogunsile, MD, a physician specializing in hematology, has been named medical director at Memorial Primary Care’s sickle cell day center.

“The addition of Dr. Ogunsile and her disease-specific expertise elevates our program and the care it can provide to patients and families.” – Melida Akiti, vice president of the Ambulatory Program and Community Services at Memorial Primary Care

In its continuous commitment to meet the needs of patients battling the genetic blood disorder of Sickle Cell, Memorial Healthcare System recently relocated its Sickle Cell Day Center, providing patients the resources of a day hospital while also offering primary care, hematology, and social services – all in one convenient location.

The stand-alone facility, under the operations of Memorial Primary Care, is now located across the street from Memorial Regional Hospital’s emergency department and serves as a ‘medical home’ for patients in need of this care.

Foluso “Joy” Ogunsile, MD, a physician specializing in hematology, has been named medical director and will lead the revamped sickle cell day center’s clinical program. She received fellowship training at Johns Hopkins Hospital and was most recently an assistant professor and researcher at the University of Alabama at Birmingham.

“The addition of Dr. Ogunsile and her disease-specific expertise elevates our program and the care it can provide to patients and families,” said Melida Akiti, vice president of the Ambulatory Program and Community Services at Memorial Primary Care. “Current and future sickle cell patients will benefit from the world-class education, medical care, lifestyle, and life care she and her team are now offering at the day center.”

Dr. Ogunsile is a graduate of both Duke University and the University of North Carolina’s medical school. Originally from Nigeria, she was a resident at Vanderbilt University Hospital before moving to Johns Hopkins to complete a fellowship.

The sickle cell day center (3700 Johnson Street, Hollywood) includes infusion suites,

equipment, and furniture that is being utilized by patients. A $300,000 contribution from the nonprofit Memorial Foundation made it possible to relocate, enhance, and expand services to the community.

Memorial Primary Care, part of Memorial Healthcare System, is dedicated to providing high-quality, compassionate, patient-centered care. With numerous locations in South Florida, its highly-skilled team of healthcare professionals works to meet each patient’s needs in a friendly and culturally-sensitive environment.

To learn more about Memorial’s approach to treating sickle cell patients, visit https://www.mhs.net/services/cancer/types/sickle-cell or call 954-265-1400.

                                                                                # # #

Memorial Healthcare System is one of the largest public healthcare systems in the U.S. and a national leader in quality care and patient, physician, and employee satisfaction. It is highly regarded for a patient and family-centered approach that prioritizes multi-disciplinary collaboration, research, innovation, and transparency.

A South Florida-based academic medical center, Memorial is committed to healing the body, mind, and spirit of those it cares for at six hospitals (including Joe DiMaggio Children’s Hospital), numerous primary, urgent, and 24/7 care facilities, a health specialty center, and nursing home.

For more information, visit mhs.net and connect on Facebook, Twitter, Instagram, YouTube, and LinkedIn.

Share article on social media or email:

Opening of the New Aunt Leah’s House for Vulnerable Moms and Babies Marks its 35th Anniversary


“For 35 years this house has been dedicated to keeping families together. During this time more than 400 families have called Aunt Leah’s house home, and we are honoured to continue to serve our community in this way,” said Sarah Stewart, Executive Director of Aunt Leah’s Place.

Aunt Leah’s Foundation announced today the completion of its most recent social purpose housing project, the rebuilding of the original Aunt Leah’s House. Operated by Aunt Leah’s Place, since the 1980’s, Aunt Leah’s House has been a safe haven for young moms (often in foster care themselves) and their babies to ensure families remain together and not separated by the child welfare system.

Through the Thresholds Program, delivered by Aunt Leah’s Place, mothers are provided with a safe and caring home environment to live in, where they learn how to care for their baby with the guidance of staff and family support workers. “For 35 years this house has been dedicated to keeping families together,” said Sarah Stewart, Executive Director of Aunt Leah’s Place. “During this time more than 400 families have called Aunt Leah’s house home, and we are honoured to continue to serve our community in this way.”

A former foster parent herself, Gale Stewart, Founder of Aunt Leah’s, and B.C. Medal of Good Citizenship Award recipient, saw first-hand the importance of “beginnings” as it applied to the bonding of mom & baby and how she could create a home where these young moms could enjoy the comfort of a lovely space, good food and intimate times with their newborns. The new purpose-built home will have four bedrooms with attached bathrooms, a large training kitchen, office space and a second stage self-contained suite that a mom can graduate into.

“Together we will continue to provide comfortable beginnings for vulnerable moms and babies, helping to re-unite and keep families together,” said Gale Stewart.

In 2020, pandemic restrictions and protocols limited the number of moms that could be accommodated in an aging house, and repairs and maintenance costs increased to the point where the original house was no longer operable. Aunt Leah’s Foundation undertook the rebuilding of the original house. The project was funded in part by the Government of Canada’s Reaching Home program, Canada Mortgage and Housing Corporation’s National Housing Co-Investment Fund and the Government of British Columbia’s Community Gaming Grants Capital Projects program, as well as a number of generous private donors. “Despite the challenges of fundraising and executing a project during pandemic times, it was the critical support of our partners, government funders and donors who believed in its importance that made it possible,” said Jacqueline Dupuis, Executive Director, Aunt Leah’s Foundation.

“Every Canadian deserves a safe and affordable place to call home,” said The Honourable Ahmed Hussen, Minister of Housing and Diversity and Inclusion. “Our government is proud to support the redevelopment of Aunt Leah’s House, a home where mothers can rest, grow and regain their independence in a safe and secure environment. At Aunt Leah’s, mothers will have the opportunity to rebuild their lives and access the critical support services necessary for them to emerge stronger. This is one way our government’s National Housing Strategy is ensuring no one is left behind.”

“Aunt Leah’s House provides a crucial service to those most vulnerable in our society. Its rebuilding ensures that more mothers and children will receive safe housing and services they need,” said Anne Kang, Minister of Municipal Affairs. “By funding important projects like this, the Province is helping support a brighter future for mothers, families and their little ones entering the world.”

About Aunt Leah’s Place

For over 30 years, Aunt Leah’s Place has been helping kids in foster care and young mothers achieve a better future. We do this by providing guidance, supported housing, job training and coaching on essential life skills. We believe every individual deserves to feel safe, cared for, and have a sense of belonging. Unfortunately, this is not a reality for many teens in the foster care system. When they “age out” of government care at 19, they find themselves completely alone. Aunt Leah’s often provides the only thread of care and continuity for youth whose lives are marked by abuse, neglect, abandonment, and multiple foster home placements. Over the years, we have seen how support at this critical time can help these young people realize their potential while becoming resilient, independent adults.

About Aunt Leah’s Foundation

In 2013, recognizing the need for more housing options, Aunt Leah’s Place launched a foundation for the purpose of building a social purpose housing portfolio that would provide safe, affordable housing for new mothers and young people leaving foster care. Today the Foundation has a portfolio of four shared-living homes and an 11-unit apartment building, housing 25-30 at-risk youth each year. Most recently the Foundation undertook a project to rebuild the original Aunt Leah’s House.

Aunt Leah’s Story: https://trellis.org/rebuild-aunt-leahs-house

Gale Stewart – BIO

Gale was born and raised rurally in southern Ontario. She graduated in Radio Television Arts at the Ryerson Polytechnic Institute (now called Toronto Metropolitan University) and moved to B.C. with a young family in 1972.

Housing has always been a very important part of Gale’s life. Finding and providing homes is her passion. They were Foster Parents during the 80’s and they saw, first-hand, the lack of housing, support and tenancy skills offered to teenagers as they aged out of the government foster care system on their 19th birthday. Through that experience and the help of many folks, she has had the privilege of founding two charities: Aunt Leah’s Place that provides support to youth and young moms leaving foster care and a partnering charity, Aunt Leah’s Foundation that buys, builds, and maintains housing for these young people.

Along with enjoying her four adult children and seven grandchildren she is currently helping to set up a Legacy Program for Aunt Leah’s Place, and she is in the early stages of writing the “Aunt Leah’s Story.”

Among many accolades for her important work, Gale is the recipient of the 2021 B.C. Medal of Good Citizenship Award.

Jacqueline Dupuis – BIO

Jacqueline moved to Vancouver in 2012 as the Executive Director of the Vancouver International Film Festival. After 8 years leading one of Vancouver’s largest arts and cultural institutions, Jacqueline followed her heart and shifted her focus to the social impact sector where she became the Executive Director of Aunt Leah’s Foundation.

Jacqueline thrives when she is working on complex problems and she believes in the role of organizations to tell powerful stories, create connection, and affect positive change in the world. Her leadership work focuses on developing growth-oriented business models and strong organizational cultures.

A travel junkie, Jacqueline has traveled the world for both work and pleasure. She has been featured in the media as both an organizational representative and public figure and was honoured to be included in the 2015 YWCA Vancouver Women of Distinction Awards.

Record-Breaking Health Care M&A Activity Recorded in 2022, According to Acquisition Data From LevinPro HC


News Image

The decline in activity we saw at the end of 2022 can be attributed to the rising interest-rate environment that represented a challenge for investors… Fears of a recession that may occur in 2023 also led to many investors re-evaluating valuations.

Health care merger and acquisition activity skyrocketed in 2022 to an all-time high of 2,395 transactions. This represented an 8% increase over the previous record of 2,214 deals recorded in 2021.

“Deal totals throughout the various sectors of health care reflect the limited downside risks faced by investors who are deploying capital in what is a significant and growing part of the U.S. economy,” said Glenn Kalinoski, Healthcare Editor at Irving Levin Associates LLC, which publishes the data on its LevinPro HC platform. “Amid declining stock markets in 2022, investors are looking for safety and what many view as predictable returns.”

Activity in the Physician Medical Groups sector soared 33% in 2022 as 608 deals were announced, compared with only 457 transactions in 2021. Biotechnology also generated a double-digit percentage rise in activity, gaining 17% with 141 deals in 2022 from 121 transactions in 2021.

The Other Services sector generated a 20% gain with 574 deals in 2022 compared with 477 transactions in 2021. Other Services includes subsectors such as ambulatory surgery centers, fertility storage solutions, health insurance support services and medical transportation services. The Medical Office Building subsector accounted for much of the increase, with 214 transactions in 2022 compared with 160 in 2021, representing a 34% jump.

Acquisitions by private equity firms continued the trend of being a more significant element of healthcare M&A activity. The 952 private equity deals in 2022 represented a 12% increase over the 852 transactions in 2021, and a 127% jump compared with the 419 deals recorded in 2020.

Headwinds began appearing in healthcare M&A activity at the end of 2022 as 547 deals were reported during the fourth quarter. This represented a 15% drop from the 647 transactions recorded during the final quarter of 2021. The first three quarters of 2022 produced increases compared to the same periods in 2021, including: 608 deals in the third quarter, representing a 17% increase over 520 transactions; 597 transactions in the second quarter for a 22% rise compared to 488 deals; and 643 deals in the first quarter, representing a 15% increase compared with 559 transactions.

Deal value in 2022 totaled $250 billion based on 482 transactions with disclosed prices. The dollar amount represented a 48% drop from 2021 when deal value reached $476.6 billion based on 615 transactions that had disclosed prices. In 2020 deal value totaled $270.6 billion based on 486 transactions with disclosed prices. The most expensive acquisition of 2022 was announced on December 12 as biopharmaceutical company Amgen Inc. purchased Horizon Therapeutics plc for $27.8 billion.

“The decline in activity we saw at the end of 2022 can be attributed to the rising interest-rate environment that represented a challenge for investors,” Kalinoski said. “Fears of a recession that may occur in 2023 also led to many investors re-evaluating valuations.”

Irving Levin Associates is celebrating 75 years of delivering exclusive M&A intelligence to its sophisticated audience of seniors housing and healthcare investors. The company was established in 1948 and has offices in New Canaan, Connecticut, and North Bethesda, Maryland. The company publishes research reports and newsletters, and maintains databases on the healthcare and senior housing M&A markets.

Share article on social media or email:

RARE-X and CoRDS Collaborate to Improve Patient Outcomes for Rare Diseases


News Image

“By collaborating with RARE-X, we can help ensure we can support expanded data collection and interoperability between existing CoRDS registries and RARE-X,” said Dr. David Pearce, president of Sanford Research.

RARE-X, the Global Genes patient-driven data collection platform, today announced a collaboration with Coordination of Rare Diseases at Sanford (CoRDS), enabling rare disease patients to better share their data and accelerate the development of diagnoses and treatments. In addition, patient advocacy groups already working with CoRDS will have the opportunity to expand and interconnect their data by leveraging RARE-X’s shared federated data platform.

With more than 10,000 rare diseases worldwide, rare disease groups struggle to compile rich, longitudinal patient data and clinical natural history data. This information is critical for patients and their doctors to understand their diseases better, entice researchers and biopharma to invest in their diseases, and help determine meaningful clinical endpoints. This collaboration will help break down data silos to make rich natural history data accessible to rare disease groups and researchers.

“CoRDS already helps link patients to researchers and clinical trials that are available for them,” said Dr. David Pearce, president of Sanford Research. “By collaborating with RARE-X, we can help ensure we can support expanded data collection and interoperability between existing CoRDS registries and RARE-X.”

RARE-X recognizes the many data gaps that exist in rare disease research and understands the importance of data sharing and data interoperability for researchers. RARE-X offers an automated and structured platform to support standardized data collection while enabling patient communities with proper governance, consent, and technology that can support a data ecosystem built for discovery.

“We are collaborating with CoRDS to expand the gathering of patient-reported outcomes from their health data,” said Charlene Son Rigby, CEO of Global Genes. “CoRDS shares the same commitment to patients as we do, and we are honored to collaborate with them to provide patients the ability to interconnect their data, making it easily accessible for researchers, to accelerate disease understanding and therapy development.”

About RARE-X

RARE-X is a program of Global Genes focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Enabled by best-in-class technology, patients, researchers, and other technology vendors, RARE-X gathers structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data-sharing technology. Through RARE-X, Global Genes is building the largest collaborative patient-driven, open-data access project for rare diseases globally. For more information, visit http://www.rare-x.org.

About Sanford Health

Sanford Health, the largest rural health system in the United States, is dedicated to transforming the health care experience and providing access to world-class health care in America’s heartland. Headquartered in Sioux Falls, South Dakota, the organization serves more than one million patients and 220,000 health plan members across 250,000 square miles. The integrated health system has 47 medical centers, 2,800 Sanford physicians and advanced practice providers, 170 clinical investigators and research scientists, more than 200 Good Samaritan Society senior care locations and world clinics in 8 countries around the globe. Learn more about Sanford Health’s commitment to shaping the future of rural health care across the lifespan at sanfordhealth.org or Sanford Health News.

About Global Genes

Global Genes is a 501(c)(3) non-profit organization dedicated to eliminating the burdens and challenges of rare diseases for patients and families globally. In pursuit of that mission, Global Genes connects, empowers, and inspires the rare disease community to stand up, stand out, and become more effective on their own behalf ⁠— helping to spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. Global Genes serves more than 400 million people around the globe, and nearly one in 10 Americans affected by rare diseases. If you or someone you love has a rare disease or are searching for a diagnosis, contact Global Genes at 949-248-RARE or visit the Resource Hub.

###

Tom Hume

Marketing Communications – Global Genes/RARE-X

tom.hume@globalgenes.org

Share article on social media or email:

Slone Partners Places Paul Wotton, Ph.D. as Chair of Board of Directors at Kytopen


Kytopen

“Paul Wotton is an extremely accomplished and talented leader and visionary in biotech, advanced cell technology, and biopharmaceutical research, discovery, and marketing,” said Slone Partners CEO Leslie Loveless.

Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Paul K. Wotton, Ph.D., as Chair of the Board of Directors at Kytopen, an MIT startup biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms.

An experienced CEO, Board Member, inventor, and serial entrepreneur, Dr. Wotton was recently named a “Top 100 Innovation CEO” by World Biz Magazine and won the Ernst & Young Entrepreneur of the Year Regional (NJ) Life Sciences award in 2014.

Over the course of his remarkable career, Dr. Wotton has served as President and Chief Executive Officer (CEO) at Ocata Therapeutics and as President and CEO of Antares Pharma. He currently serves on the Board of Directors of Vericel Corporation (NASDAQ: VCEL) and Cynata Therapeutics (ASX: CYP) and is a founder of Avenge Bio.

“Paul Wotton is an extremely accomplished and talented leader and visionary in biotech, advanced cell technology, and biopharmaceutical research, discovery, and marketing,” said Slone Partners CEO Leslie Loveless. “He brings tremendous passion and depth of knowledge to his new role as Chair of the Board of Directors at Kytopen.”

“We are thrilled to welcome Paul Wotton to join and lead the Kytopen Board of Directors,” said Dr. Paulo Garcia, CEO and Co-Founder of Kytopen. “Dr. Wotton not only brings significant experience growing biotech companies but also has the vision and aspiration to help Kytopen deliver on our mission to expand patient access to the next generation of living medicines.”

Dr. Wotton commented, “I am very pleased to join Kytopen at such an exciting time in our industry. Kytopen’s proprietary non-viral delivery technology solves a major bottleneck in the process of gene-modified cell therapy discovery, development, and manufacturing; a bottleneck that keeps costs high, limits productivity, and constrains patient access to potentially life-saving medicines.”

Dr. Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham.

ABOUT SLONE PARTNERS

Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, medical device, and laboratory services companies. With national and global clients, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences and healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.

ABOUT KYTOPEN

Kytopen is an MIT startup developing platforms to accelerate the discovery, development, and manufacturing of gene-modified cell therapies. The scalable Flowfect® solution combines microfluidics and automation to make this process easier, faster, and more cost-effective than the state-of-the art solutions. In 2017, Dr. Paulo Garcia co-founded Kytopen with Dr. Cullen Buie. Together they co-invented Kytopen’s proprietary Flowfect® technology for high-throughput genetic modification of cells. For more information, visit http://www.kytopen.com and follow @kytopen on Twitter and LinkedIn. Kytopen products are provided for Research Use Only.

Share article on social media or email: